[suzierose]

Hello Beacon Staff

by suzierose on Mon Jan 09, 2012 6:11 pm

Are you able to get slides of Dr Neben's presentation from ASH2011?

Dr. Neben - Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial
Kai Neben, MD
Universitaetsklinikum Heidelberg
Heidelberg, Germany

[Beacon Staff]

Re: Hello Beacon Staff

by Beacon Staff on Mon Jan 09, 2012 9:52 pm

Hi suzierose,

Thanks for your question.

We don't request presentations from an author unless we are planning on covering the presentation in an article for The Beacon. That's not currently the case with this presentation, so we're not comfortable requesting a copy of it.

However, you may be able to get a copy yourself by emailing Dr. Neben on your own. His email address is listed on this page:

http://www.klinikum.uni-heidelberg.de/Neben-Kai.118667.0.html

Good luck!

[Dr. Peter Voorhees]

Re: Hello Beacon Staff

by Dr. Peter Voorhees on Mon Jan 09, 2012 10:37 pm

Dear Suzierose,

The MRC has also published in this area. Additionally, the GMMG have published results from the patients on the HOVON-65/GMMG HD4 trial treated in Germany and the impact of specific chromosome abnormalities on outcome. The results are those that they presented at ASH. Interestingly, in their hands, patients with 17p deletions who were assigned to the Velcade (bortezomib) arm of the study (Velcade with induction followed by tandem autologous stem cell transplant followed by Velcade maintenance) did as well as those who did not carry the 17p deletion, suggesting longer term exposure to Velcade may be advantageous for this group of patients. Realize that these patients also received tandem transplants, so the treatment approach was on the aggressive side of things.

The MRC data, as we have discussed previously, suggests that:

1) the more adverse cytogenetic abnormalities you have, the harder the disease is to treat; and
2) incorporating the international stage provides additional prognostic information.

The GMMG also found point #2 to be the case. They did not look at combinations of chromosome abnormalities (there were not as many patients, which makes that kind of analysis difficult from a statistical perspective).

PubMed links ar as follows:

http://www.ncbi.nlm.nih.gov/pubmed/22160383
http://www.ncbi.nlm.nih.gov/pubmed/21836613

I hope this helps!

Pete V.